Single-arm trial shows empagliflozin reduces epicardial adipose tissue in type 2 diabetes patients, suggesting implications for cardiac health.
Empagliflozin therapy was associated with significant EAT thinning and favorable within-subject changes in selected diastolic indices and cardiometabolic markers in T2DM patients without established cardiovascular disease. The magnitude of EAT reduction was not significantly correlated with changes in conventional metabolic or inflammatory parameters; however, given the single-arm design and absence of a control group, causal and mechanistic inferences cannot be made, and these findings should be considered hypothesis-generating. Future controlled studies are warranted to confirm these observations and clarify underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Ceylan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: